Association Analysis of Maximum Standardized Uptake Values Based on 18F-FDG PET/CT and EGFR Mutation Status in Lung Adenocarcinoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Selection and Characteristics
2.2. PET/CT Imaging
2.3. Image Analysis
2.4. EGFR Mutation Test
2.5. Statistical Analysis
3. Results
3.1. The General Data, Morphological Features, SUVmax, and Pathological Subtypes of the Two Patient Groups
3.2. Interaction Analysis
3.3. Multivariable Regression for the Association between SUVmax and EGFR Mutation Probability in Smoking Subgroups
3.4. Curve Fitting
4. Discussion
Strengths and Limitations of This Study
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454. [Google Scholar] [CrossRef] [PubMed]
- Xia, C.; Dong, X.; Li, H.; Cao, M.; Sun, D.; He, S.; Yang, F.; Yan, X.; Zhang, S.; Li, N.; et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin. Med. J. 2022, 135, 584–590. [Google Scholar] [CrossRef] [PubMed]
- Suda, K.; Mitsudomi, T. Role of EGFR mutations in lung cancers: Prognosis and tumor chemosensitivity. Arch. Toxicol. 2015, 89, 1227–1240. [Google Scholar] [CrossRef] [PubMed]
- da Cunha Santos, G.; Shepherd, F.A.; Tsao, M.S. EGFR mutations and lung cancer. Annu. Rev. Pathol. 2011, 6, 49–69. [Google Scholar] [CrossRef] [Green Version]
- Shi, Y.; Au, J.S.; Thongprasert, S.; Srinivasan, S.; Tsai, C.M.; Khoa, M.T.; Heeroma, K.; Itoh, Y.; Cornelio, G.; Yang, P.C. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2014, 9, 154–162. [Google Scholar] [CrossRef] [Green Version]
- Recondo, G.; Facchinetti, F.; Olaussen, K.A.; Besse, B.; Friboulet, L. Making the first move in EGFR-driven or ALK-driven NSCLC: First-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 2018, 15, 694–708. [Google Scholar] [CrossRef]
- Tan, C.S.; Gilligan, D.; Pacey, S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015, 16, e447–e459. [Google Scholar] [CrossRef]
- Devarakonda, S.; Morgensztern, D.; Govindan, R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015, 16, e342–e351. [Google Scholar] [CrossRef]
- Zhang, Y.; Chang, L.; Yang, Y.; Fang, W.; Guan, Y.; Wu, A.; Hong, S.; Zhou, H.; Chen, G.; Chen, X.; et al. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Mol. Cancer 2019, 18, 7. [Google Scholar] [CrossRef]
- Li, Z.; Zhang, Y.; Bao, W.; Jiang, C. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: A meta-analysis. Target Oncol. 2014, 9, 381–388. [Google Scholar] [CrossRef]
- Jiang, M.; Zhang, X.; Chen, Y.; Chen, P.; Guo, X.; Ma, L.; Gao, Q.; Mei, W.; Zhang, J.; Zheng, J. A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. Front. Oncol. 2022, 12, 780186. [Google Scholar] [CrossRef]
- Shi, A.; Wang, J.; Wang, Y.; Guo, G.; Fan, C.; Liu, J. Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer. Ann. Nucl. Med. 2022, 36, 393–400. [Google Scholar] [CrossRef]
- Ni, M.; Wang, S.; Liu, X.; Shi, Q.; Zhu, X.; Zhang, Y.; Xie, Q.; Lv, W. Predictive value of intratumor metabolic and heterogeneity parameters on [18F]FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma. Jpn. J. Radiol. 2023, 41, 209–218. [Google Scholar] [CrossRef]
- Minamimoto, R.; Jamali, M.; Gevaert, O.; Echegaray, S.; Khuong, A.; Hoang, C.D.; Shrager, J.B.; Plevritis, S.K.; Rubin, D.L.; Leung, A.N.; et al. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Oncotarget 2017, 8, 52792–52801. [Google Scholar] [CrossRef] [Green Version]
- Caicedo, C.; Garcia-Velloso, M.J.; Lozano, M.D.; Labiano, T.; Vigil Diaz, C.; Lopez-Picazo, J.M.; Gurpide, A.; Zulueta, J.J.; Richter Echevarria, J.A.; Perez Gracia, J.L. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 2058–2065. [Google Scholar] [CrossRef]
- Kanmaz, Z.D.; Aras, G.; Tuncay, E.; Bahadir, A.; Kocaturk, C.; Yasar, Z.A.; Oz, B.; Ozkurt, C.U.; Gundogan, C.; Cermik, T.F. Contribution of 18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. Cancer Biomark. 2016, 16, 489–498. [Google Scholar] [CrossRef]
- Lee, E.; Khong, P.L.; Lee, V.; Qian, W.; Wong, M.P. Metabolic phenotype of stage IV lung adenocarcinoma: Relationship with epidermal growth factor receptor mutation. Clin. Nucl. Med. 2015, 40, e190. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.M.; Bae, S.K.; Jung, S.J.; Kim, C.K. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: A retrospective analysis of 206 patients. Clin. Nucl. Med. 2015, 40, 950–958. [Google Scholar] [CrossRef]
- Travis, W.D.; Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.R.; Yatabe, Y.; Beer, D.G.; Powell, C.A.; Riely, G.J.; Van Schil, P.E.; et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6, 244–285. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Cai, W.; Wang, Y.; Liao, M.; Tian, S. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: A systematic review and meta-analysis. Int. J. Clin. Oncol. 2019, 24, 649–659. [Google Scholar] [CrossRef]
- Wang, H.; Guo, H.; Wang, Z.; Shan, B.; Lin, J. The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma. Biomed. Res. Int. 2019, 2019, 9643836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moreira, A.L.; Ocampo, P.S.S.; Xia, Y.; Zhong, H.; Russell, P.A.; Minami, Y.; Cooper, W.A.; Yoshida, A.; Bubendorf, L.; Papotti, M.; et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J. Thorac. Oncol. 2020, 15, 1599–1610. [Google Scholar] [CrossRef] [PubMed]
- Fujikawa, R.; Muraoka, Y.; Kashima, J.; Yoshida, Y.; Ito, K.; Watanabe, H.; Kusumoto, M.; Watanabe, S.I.; Yatabe, Y. Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the IASLC Grading System. J. Thorac. Oncol. 2022, 17, 700–707. [Google Scholar] [CrossRef] [PubMed]
- Gu, J.; Xu, S.; Huang, L.; Li, S.; Wu, J.; Xu, J.; Feng, J.; Liu, B.; Zhou, Y. Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. J. Thorac. Dis. 2018, 10, 723–731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaira, K.; Serizawa, M.; Koh, Y.; Takahashi, T.; Yamaguchi, A.; Hanaoka, H.; Oriuchi, N.; Endo, M.; Ohde, Y.; Nakajima, T.; et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung. Cancer 2014, 83, 197–204. [Google Scholar] [CrossRef]
- Chen, L.; Zhou, Y.; Tang, X.; Yang, C.; Tian, Y.; Xie, R.; Chen, T.; Yang, J.; Jing, M.; Chen, F.; et al. EGFR mutation decreases FDG uptake in nonsmall cell lung cancer via the NOX4/ROS/GLUT1 axis. Int. J. Oncol. 2019, 54, 370–380. [Google Scholar] [CrossRef] [Green Version]
- Byun, Y.S.; Yoo, Y.S.; Kwon, J.Y.; Joo, J.S.; Lim, S.A.; Whang, W.J.; Mok, J.W.; Choi, J.S.; Joo, C.K. Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation. Exp. Eye Res. 2016, 143, 89–97. [Google Scholar] [CrossRef] [Green Version]
- Liu, Q.; Sun, D.; Li, N.; Kim, J.; Feng, D.; Huang, G.; Wang, L.; Song, S. Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features. Transl. Lung. Cancer Res. 2020, 9, 549–562. [Google Scholar] [CrossRef]
- Ko, K.H.; Hsu, H.H.; Huang, T.W.; Gao, H.W.; Shen, D.H.; Chang, W.C.; Hsu, Y.C.; Chang, T.H.; Chu, C.M.; Ho, C.L.; et al. Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1889–1897. [Google Scholar] [CrossRef]
- Chang, C.; Zhou, S.; Yu, H.; Zhao, W.; Ge, Y.; Duan, S.; Wang, R.; Qian, X.; Lei, B.; Wang, L.; et al. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma. Eur. Radiol. 2021, 31, 6259–6268. [Google Scholar] [CrossRef]
- Usuda, K.; Sagawa, M.; Motono, N.; Ueno, M.; Tanaka, M.; Machida, Y.; Matoba, M.; Taniguchi, M.; Tonami, H.; Ueda, Y.; et al. Relationships between EGFR mutation status of lung cancer and preoperative factors—Are they predictive? Asian Pac. J. Cancer Prev. 2014, 15, 657–662. [Google Scholar] [CrossRef] [Green Version]
- Lv, Z.; Fan, J.; Xu, J.; Wu, F.; Huang, Q.; Guo, M.; Liao, T.; Liu, S.; Lan, X.; Liao, S.; et al. Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: A retrospective analysis of 849 Chinese patients. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 735–750. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Zhao, X.; Zhao, Y.; Zhang, J.; Zhang, Z.; Wang, J.; Wang, Y.; Dai, M.; Han, J. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1137–1146. [Google Scholar] [CrossRef]
- Mu, W.; Jiang, L.; Zhang, J.; Shi, Y.; Gray, J.E.; Tunali, I.; Gao, C.; Sun, Y.; Tian, J.; Zhao, X.; et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat. Commun. 2020, 11, 5228. [Google Scholar] [CrossRef]
- Li, S.; Li, Y.; Zhao, M.; Wang, P.; Xin, J. Combination of 18F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Korean J. Radiol. 2022, 23, 921–930. [Google Scholar] [CrossRef]
- Nair, J.K.R.; Saeed, U.A.; McDougall, C.C.; Sabri, A.; Kovacina, B.; Raidu, B.V.S.; Khokhar, R.A.; Probst, S.; Hirsh, V.; Chankowsky, J.; et al. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer. Can. Assoc. Radiol. J. 2021, 72, 109–119. [Google Scholar] [CrossRef]
EGFR | Wild-Type | Mutant | p-Value |
---|---|---|---|
n | 138 | 228 | |
Age (years) | 64.9 (9.2) | 63.6 (9.2) | 0.209 |
Gender | <0.001 | ||
Female | 44 (31.9%) | 150 (65.8%) | |
Male | 94 (68.1%) | 78 (34.2%) | |
Smoking history | 78 (56.5%) | 53 (23.3%) | <0.001 |
Nodule type | <0.001 | ||
Solid | 105 (76.1%) | 131 (57.5%) | |
Subsolid | 33 (23.9%) | 97 (42.5%) | |
Location | 0.807 | ||
Upper right | 42 (30.4%) | 77 (33.8%) | |
Middle right | 6 (4.4%) | 14 (6.1%) | |
Lower right | 27 (19.6%) | 45 (19.7%) | |
Upper left | 38 (27.5%) | 59 (25.9) | |
Lower left | 25 (18.1%) | 33 (14.5%) | |
Shape | 0.153 | ||
round/oval | 82 (59.4%) | 118 (51.8%) | |
Polygon/Irregular | 56 (40.6%) | 110 (48.3%) | |
Lobulation sign | 116 (84.1%) | 194 (85.1%) | 0.791 |
Burr sign | 71 (51.5%) | 128 (56.1%) | 0.383 |
Bronchial sign | 59 (42.8%) | 140 (61.4%) | <0.001 |
Vacuolation sign | 21 (15.2%) | 30 (13.2%) | 0.581 |
Pleural indentation sign | 71 (51.5%) | 166 (72.8%) | <0.001 |
Vascular bundle sign | 70 (50.7%) | 146 (64.0%) | 0.012 |
Tumor long axis (mm) | 32.0 (20.6–45.3) | 25.0 (19.8–35.2) | 0.001 |
CEA (ng/mL) | 4.71 (2.5–14.6) | 3.5 (1.6–12.3) | 0.096 |
Clinical stage | 0.004 | ||
I | 49 (35.5%) | 126 (55.3%) | |
II | 11 (8.0%) | 3 (1.3%) | |
III | 27 (19.6%) | 32 (14.0%) | |
IV | 51 (37.0%) | 67 (29.4%) | |
SUVmax | 12.3 (5.8–17.5) | 9.0 (3.3–16.5) | 0.004 |
Exposure | Non-Adjusted | Adjust I | Adjust II |
---|---|---|---|
OR (95%CI) p Value | OR (95%CI) p Value | OR (95%CI) p Value | |
SUVmax | 0.948 (0.912, 0.986) 0.007 | 0.946 (0.907, 0.986) 0.009 | 0.952 (0.908, 0.999) 0.045 |
SUVmax Tertile | |||
Tertile 1 (0.94–9.98) n = 44 | 1.0 | 1.0 | 1.0 |
Tertile 2 (10.61–17.48) n = 43 | 0.294 (0.120, 0.720) 0.007 | 0.263 (0.103, 0.673) 0.005 | 0.292 (0.105, 0.811) 0.018 |
Tertile 3 (17.57–67.17) n = 44 | 0.434 (0.184, 1.022) 0.056 | 0.387 (0.156, 0.962) 0.041 | 0.393 (0.136, 1.134) 0.084 |
p for trend | 0.052 | 0.039 | 0.090 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gao, J.; Shi, Y.; Niu, R.; Shao, X.; Shao, X. Association Analysis of Maximum Standardized Uptake Values Based on 18F-FDG PET/CT and EGFR Mutation Status in Lung Adenocarcinoma. J. Pers. Med. 2023, 13, 396. https://doi.org/10.3390/jpm13030396
Gao J, Shi Y, Niu R, Shao X, Shao X. Association Analysis of Maximum Standardized Uptake Values Based on 18F-FDG PET/CT and EGFR Mutation Status in Lung Adenocarcinoma. Journal of Personalized Medicine. 2023; 13(3):396. https://doi.org/10.3390/jpm13030396
Chicago/Turabian StyleGao, Jianxiong, Yunmei Shi, Rong Niu, Xiaoliang Shao, and Xiaonan Shao. 2023. "Association Analysis of Maximum Standardized Uptake Values Based on 18F-FDG PET/CT and EGFR Mutation Status in Lung Adenocarcinoma" Journal of Personalized Medicine 13, no. 3: 396. https://doi.org/10.3390/jpm13030396